Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
